MDMA‐assisted therapy for PTSD reduced symptoms in Phase 3 trial
The Brown University Psychopharmacology Update January 1, 2024 Peer reviewed DOI: 10.1002/pu.31105
Summary
MDMA-assisted therapy over three sessions in three months significantly improved symptoms of post-traumatic stress disorder (PTSD) compared to placebo plus therapy. Additionally, it led to improvements in functional impairment measures.
Study at a glance
| Design | Phase 3 trial |
|---|---|
| Population | individuals with post-traumatic stress disorder (PTSD) |
| Key finding | MDMA-assisted therapy significantly improved PTSD symptoms compared to placebo plus therapy. |
Abstract
Three sessions of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy over 3 months significantly improved symptoms of post‐traumatic stress disorder (PTSD) compared with placebo plus therapy in a Phase 3 trial. MDMA‐assisted therapy also resulted in improvement in a measure of functional impairment. Study results were published online Sept. 14, 2023, in Nature Medicine.